Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), Route of administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Type ( Human vaccine , Veterinary vaccine) - Global Forecast to 2028
The global vaccine adjuvants market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 6.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the market can be attributed to various factors such as the rising prevalence of infectious diseases and increase in number of vaccine approavls across the globe.
Attractive Opportunities in the Vaccine Adjuvants Market
To know about the assumptions considered for the study, Request for Free Sample Report
Vaccine Adjuvants Market Dynamics
Driver: Rising prevalence of infectious diseases
The prevalence of infectious diseases, such as influenza, tuberculosis, cholera, polio, measles, malaria, and HIV, among others, has increased. According to the WHO, TB was 13th leading cause of death worldwide and the second-leading infectious killer after COVID-19 in 2021, globally there were almost 1.6 million deaths reported including 187,000 people with HIV. The rising cases has ultimately built a pressure on vaccine production since more vaccines would be required to cure such contagious disease and resulting in increase in demand for adjuvants.
Restraint: Side Effects and High Toxicity of Adjuvants
The Vaccine adjuvants have various limitations, such as side effects and high toxicity, which can hinder the overall market growth. For instance, aluminum-adjuvanted AVA vaccine used in Anthrax vaccine is administered through subcutaneous route is found to be associated with swelling that can pinch the ulnar nerve and can lead to distal paresthesia.
Opportunity: Rising funding for vaccines and infectious disease research activities
With the emergence of COVID-19, and various contagious diseases, government authorities and pharmaceutical & biotechnology companies have recognized the importance of research on infectious diseases. For instance in 2023, the Engineering and Physical Sciences Research Council (EPSRC), a part of UK Research and Innovation (UKRI) announced a funding of almost USD 13 million in order to provide financial assistance to Future Vaccines Manufacturing Hub for next seven years .
Challenge: Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing
Squalene is derived from shark liver oil used as a ingredient in some adjuvants. This has led to the mass slaughtering of shark population and has ultimately imbalance the aquatic life. According to the conservationist group Shark Allies, almost 250,000 sharks need to be killed for the development of one COVID-19 vaccine dose for the global population. This has placed the shark population on the verge of extinction and serve as the major challenge for vaccine adjuvant market.
Vaccine Adjuvants Market – Ecosystem
The adjuvant emulsions segment of the vaccine adjuvants industry is projected to hold the dominant position during the forecast period:
On the basis of product, the global vaccine adjuvants market is divided into various segments: adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other adjuvants. Among these, the adjuvant emulsions segment is projected to maintain its dominant position. This is primarily attributed to the increasing prevalence of communicable diseases, driving the utilization of emulsion adjuvants in vaccines and subsequently fostering the growth of this segment.
North America was the largest regional market for vaccine adjuvants industry in 2022.
The market is divided into five key regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America held the largest market share in 2022, and this trend is predicted to continue. The growth in this region's vaccine adjuvants market is driven by increased investments from governments and nonprofit organizations in adjuvant development. Strategic decisions like partnerships and collaborations among key market players for vaccine research and development also contribute to the market's expansion in the region.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the market include Dynavax Technologies (US), GSK plc (UK), Croda International plc (UK), Seppic (France), Novavax (US), SPI Pharma (Associated British Foods plc) (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (Vertellus) (US), Merck KGaA (Germany), Vaxine Pty Ltd. (Australia), Hawaii Biotech Inc. (US), CSL Limited (Australia), OZ Biosciences (US), InvivoGen (US), Allergy Therapeutics (UK), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US) Riboxx GmbH (Germany), CaPtivate Pharmaceuticals LLC (US), Creative Diagnostics (US), LiteVax BV (Netherlands), Mukta Industries (India), Oncovir, Inc. (US), and TiterMax USA, Inc. (US).
Scope of the Vaccine Adjuvants Industry:
|
Report Metric |
Details |
|
Market Revenue in 2023 |
$0.8 billion |
|
Estimated Value by 2028 |
$1.2 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 6.9% |
|
Market Driver |
Rising prevalence of infectious diseases |
|
Market Opportunity |
Rising funding for vaccines and infectious disease research activities |
This report categorizes the vaccine adjuvants market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Adjuvant Emulsions
- Pathogen Components
- Saponin-based adjuvants
- Particulate Adjuvants
- Other Adjuvants
By Route of Administration
- Intramuscular
- Subcutaneous
- Other Route of Administration
By Disease Type
- Infectious Diseases
- Cancer
- Others
By Application
- Research Applications
- Commercial Applications
By Type
- Human Vaccine Adjuvants
- Veterinary Vaccine Adjuvants
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments of Vaccine Adjuvants Industry
- In May 2023 Croda International Plc (UK) entered into a partnership with Amyris (US) and Botanical Solutions Inc. (BSI) firstly for biotechnology-derived squalene and secondly with BSI for develop a sustainable QS-21 vaccine adjuvant moving towards plant tissue culture-derived approach rather than traditional method of extracting QS-21 from soap bark trees.
- In August 2022, GSK Plc (UK) entered into acquisition with Affinivax, Inc. (US) in order to develop pneumococcal vaccines.
- In October 2021, Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global vaccine adjuvants market?
The global vaccine adjuvants market boasts a total revenue value of $1.2 billion by 2028.
What is the estimated growth rate (CAGR) of the global vaccine adjuvants market?
The global vaccine adjuvants market has an estimated compound annual growth rate (CAGR) of 6.9% and a revenue size in the region of $0.8 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
This study involved four major activities in estimating the current size of the vaccine adjuvants market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the vaccine adjuvants market. The secondary sources used for this study include National Institute of Cancer (NIC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), National Institute of Allergy and Infectious Diseases (NIAID), United States Department of Health and Human Services, United States Agency for International Development, International Society for Vaccines, UNICEF, GAVI, PAHO, Medical Research Council. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global vaccine adjuvants market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the vaccine adjuvants market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The major players in the industry and market have been identified through extensive primary and secondary research.
- The revenues generated from the vaccine adjuvants business of players operating in the market have been determined through secondary research and primary analysis.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Global Vaccine Adjuvants Market Size: Bottom-Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global Vaccine Adjuvants Market Size: Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
An adjuvant is a substance that is included in a vaccine formulation to enhance the immune-stimulating properties of a vaccine to the antigen. There are various functions of an adjuvant, such as increasing immunogenicity, enhancing the magnitude, breadth and durability of the immune response, and improving the efficacy of a vaccine. Adjuvants are used in different types of human and veterinary vaccines to prevent various diseases
Key Stakeholders
- Vaccine adjuvant manufacturers
- Vaccine manufacturers
- Vaccine adjuvant associations
- Vaccine adjuvant research institutes
- Vaccine product distributors
- Vaccine adjuvant raw material suppliers
- Vaccine adjuvant development institutes and organizations
- Biotechnology & biopharmaceutical companies
- Drug manufacturers, vendors, and distributors
- Academic & government research institutes
- Venture capitalists & investors
- Government organizations
- Private research firms
- Research & development (R&D) companies
Report Objectives
- To define, describe, and forecast the vaccine adjuvants market by product, route of administration, disease type, application, type, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall vaccine adjuvants market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East & Africa (MEA)
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, acquisitions partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country-wise Information:
- Analysis for additional countries (up to five)
Company Information:
- Detailed analysis and profiling of additional market players (up to five)
Generating Response ...
Growth opportunities and latent adjacency in Vaccine Adjuvants Market